Center for iPS Cell Research and Application, Kyoto University, Sakyo-ku, Kyoto, Japan.
J Mol Cell Cardiol. 2011 Feb;50(2):327-32. doi: 10.1016/j.yjmcc.2010.10.026. Epub 2010 Oct 30.
For the treatment of heart failure, a new strategy to improve cardiac function and inhibit cardiac remodeling needs to be established. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are pluripotent cells that can differentiate into cell types from all three germ layers both in vitro and in vivo. The therapeutic effect of ES/iPS cell-derived progeny was reported in animal model. Mouse and human somatic cells can be reprogrammed to induced pluripotent stem cells (iPSCs) by the transduction of four transcription factors, Oct 3/4, Sox2, Klf4, and c-Myc. However, the low induction efficiency hinders the clinical application of iPS technology, and efforts have been made to improve the reprogramming efficiency. There are variations in the characteristics in ES/iPS cell lines, and the further understanding is necessary for the applications of ES/iPS cell technology. Some improvements were also made in the methods to induce cardiomyocytes from ES/iPS cells efficiently. This review article is focused on generation of iPS cells, cardiomyocyte differentiation from ES/iPS cells, and transplantation of derived cardiomyocytes.This article is part of a special issue entitled, "Cardiovascular Stem Cells Revisited".
为了治疗心力衰竭，需要建立一种新的策略来改善心脏功能并抑制心脏重构。胚胎干细胞（ESCs）和诱导多能干细胞（iPSCs）是多能细胞，它们可以在体外和体内分化为来自三个胚层的细胞类型。在动物模型中已经报道了 ES/iPS 细胞衍生后代的治疗效果。通过转导四个转录因子（Oct3/4、Sox2、Klf4 和 c-Myc），可以将小鼠和人类体细胞重编程为诱导多能干细胞（iPSCs）。然而，低诱导效率阻碍了 iPS 技术的临床应用，人们一直在努力提高重编程效率。ES/iPS 细胞系在特征上存在差异，需要进一步了解 ES/iPS 细胞技术的应用。在从 ES/iPS 细胞高效诱导心肌细胞的方法上也有一些改进。本文主要关注 iPS 细胞的产生、ES/iPS 细胞向心肌细胞的分化以及衍生心肌细胞的移植。本文是题为“心血管干细胞再探讨”的特刊的一部分。
